Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kyverna Therapeutics, Inc. - Common Stock
(NQ:
KYTX
)
10.82
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,354
Open
10.82
Bid (Size)
9.720 (300)
Ask (Size)
10.16 (300)
Prev. Close
10.82
Today's Range
10.82 - 10.82
52wk Range
1.780 - 13.67
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity
↗
December 15, 2025
Today, Dec. 15, 2025, stocks dipped as growth shares faltered and traders assessed trade risk alongside Fed commentary.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Stocks
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
December 15, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+176.0%
+176.0%
1 Month
+51.1%
+51.1%
3 Month
+176.7%
+176.7%
6 Month
+243.5%
+243.5%
1 Year
+155.2%
+155.2%
More News
Read More
Which stocks are moving on Monday?
↗
December 15, 2025
Via
Chartmill
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
December 15, 2025
Via
AB Newswire
Monday's session: top gainers and losers
↗
December 15, 2025
Via
Chartmill
Which stocks are gapping on Monday?
↗
December 15, 2025
Via
Chartmill
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?
↗
December 15, 2025
Via
Stocktwits
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
December 15, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
December 14, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
November 20, 2025
Via
Benzinga
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
November 10, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
↗
November 04, 2025
Via
Benzinga
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
November 03, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
October 29, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
October 25, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
October 22, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Top movers in Wednesday's session
↗
October 08, 2025
Via
Chartmill
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 02, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
September 24, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
September 15, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
August 28, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
August 25, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
↗
August 20, 2025
Via
Benzinga
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 12, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
The current price of Kyverna Therapeutics, Inc. - Common Stock is 10.82
When was Kyverna Therapeutics, Inc. - Common Stock last traded?
The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 12/15/25 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today